Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood

Korea University

Status: Enrolling

Conditions: Diagnosis; Lung Cancer

Treatments: Diagnostic Test: frozen blood plasma samples

Study type: Observational

Funder types: Other

Identifiers

NCT05587114

2020GR0340

Details and patient eligibility

About

Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies.

This study is a retrospective blood sample obtained and prospectively comparative analysis of various biomarkers (cancer markers, and exosome markers) derived from peripheral blood and pulmonary venous blood from patients who underwent lung cancer surgery.

And treatment monitoring using biomarkers compare with peripheral and pulmonary blood.

Enrollment: 150 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with Korean nationality
• Patients who did not receive neoadjuvant therapy before surgery
• Patients not diagnosed with any other cancer before surgery
• Patients who agreed to the consent form for a donation of human materials during surgery

Exclusion criteria

• Patients who do not meet the inclusion criteria